Compare Abbott Laboratories (ABT) vs Align Technology, Inc. (ALGN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Align Technology, Inc. — how do they compare? Abbott Laboratories trades at $95.6 (market cap $166.94B), while Align Technology, Inc. trades at $176.22 (market cap $13.27B). The key difference: Abbott Laboratories is far larger — about 12.6× Align Technology, Inc.'s market cap, and Abbott Laboratories pays a 2.63% dividend while Align Technology, Inc. pays none. Which is the better fit depends on your goals.
| ABT | ALGN | |
|---|---|---|
Market Cap | $166.94B | $13.27B |
Sector | Health | Health |
52-Week High | $136.62 | $207.19 |
52-Week Low | $82.57 | $124.88 |
Enterprise Value | $193.69B | $12.32B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
ALGN trades at $185.22, up 0.38% today, with a bullish technical signal and strong analyst consensus. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 results expected soon. Revenue remains stable around $4.0B, supported by a 67.57% gross margin and positive cash flow trends. Recent news highlights global expansion and product innovation, including a new manufacturing facility in India.
Outlook is positive with a $220.75 consensus price target, though risks include regulatory scrutiny from the European Commission and competitive pressures. The stock's valuation at a P/E of 31.65 reflects growth expectations, but investors should monitor execution on international growth and demand stability in North America.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Align Technology, Inc.
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →
